Elevated VCP ATPase Activity Correlates With Disease Onset in Multisystem Proteinopathy-1

Sarah E. Robinson, Andrew R. Findlay, Shan Li, Feng Wang, Marianela Schiava, Jil Daw, Jordi Diaz-Manera, Tsui Fen Chou, Conrad Weihl

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives Multisystem proteinopathy-1 (MSP1) is a late onset disease with >50 pathogenic variants in p97/VCP. MSP1 patients have multiple phenotypes that include inclusion body myopathy, Paget disease of the bone, amyotrophic lateral sclerosis, and frontotemporal dementia. There have been no clear genotype-phenotype correlations. We sought to identify genotype-phenotype correlations and associate these with VCP intrinsic ATPase activity. Methods Patients with MSP1 were identified from the literature and the Cure VCP patient registry. Age at onset and at loss of ambulation were collated. VCP intrinsic ATPase activity was evaluated from recombinant purified protein. Results Among the 5 most common pathogenic VCP variants in MSP1 patients, R155C patients had the earliest average age at onset (38.15 ± 9.78). This correlated with higher ATPase activity. Evaluation of 5 variants confirmed an inverse correlation between age at onset and ATPase activity (r = −0.94, p = 0.01). Discussion Previous studies have reported that VCP pathogenic variants are “hyperactive.” Whether this elevation in VCP ATPase activity is relevant to disease is unclear. Our study supports that in vitro VCP activity correlates with disease onset and may guide the prognosis of patients with rare or unreported variants. Moreover, it suggests that inhibition of VCP ATPase activity in MSP1 may be therapeutic.

Original languageEnglish
Article numbere200191
JournalNeurology: Genetics
Volume10
Issue number5
DOIs
StatePublished - Sep 12 2024

Fingerprint

Dive into the research topics of 'Elevated VCP ATPase Activity Correlates With Disease Onset in Multisystem Proteinopathy-1'. Together they form a unique fingerprint.

Cite this